| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Neuropeptides B and W receptor 1 (NPBWR1); GPR7
|
|---|---|
| ln Vitro |
In a dose-dependent manner, CYM 50769 (1 and 3 μM; 30 min) inhibits the proliferation of ATDC5 cells caused by NPW-23 [1].
In this Letter researchers report on the advances in their NPBWR1 antagonist program aimed at optimizing the 5-chloro-2-(3,5-dimethylphenyl)-4-(4-methoxyphenoxy)pyridazin-3(2H)-one lead molecule previously obtained from a high-throughput screening (HTS)-derived hit. Synthesis and structure-activity relationships (SAR) studies around the 3,5-dimethylphenyl and 4-methoxyphenyl regions resulted in the identification of a novel series of non-peptidic submicromolar NPBWR1 antagonists based on a 5-chloro-4-(4-alkoxyphenoxy)-2-(benzyl)pyridazin-3(2H)-one chemotype. Amongst them, 5-chloro-2-(9H-fluoren-9-yl)-4-(4-methoxyphenoxy)pyridazin-3(2H)-one 9h (CYM50769) inhibited NPW activation of NPBWR1 with a submicromolar IC(50), and displayed high selectivity against a broad array of off-targets with pharmaceutical relevance. Our medicinal chemistry study provides innovative non-peptidic selective NPBWR1 antagonists that may enable to clarify the biological role and therapeutic utility of the target receptor in the regulation of feeding behavior, pain, stress, and neuroendocrine function. [1] |
| Cell Assay |
Cell Proliferation Assay
Cell Types: ATDC5 (24 hrs (hours) exposure to 200 ng/mL NPW-23) [1] Tested Concentrations: 1 and 3 μM Incubation Duration: 30 minutes Experimental Results: Attenuation of NPW-23-induced cell proliferation in a dose-dependent manner . |
| References | |
| Additional Infomation |
Of the synthesized compounds, compound 9h (CYM50769) was selected for further characterization. Compound 9h has a solubility of 0.17 μM in phosphate-buffered saline (PBS) at pH 7.4. This compound exhibits no cytotoxicity against U2OS cells at a concentration of 20 μM and is chemically stable in PBS at pH 7.4 with a half-life greater than 48 hours. At a concentration of 30 μM, its selectivity was investigated using a Ricerca target protein library (containing G protein-coupled receptors, enzymes, transporters, and ion channels). Notably, among the 35 targets tested, only CYP450 1A2, 5-HT2B, and CYP450 2C19 showed inhibition rates of 67%, 63%, and 51%, respectively. In summary, we report the synthesis of novel non-peptide NPBWR1 antagonists based on the 5-chloro-4-(4-alkoxyphenoxy)-2-(benzyl)pyridazine-3(2H)-one chemistry and their structure-activity relationship studies around the helical region and the 4-methoxyphenyl region (a, b). Small changes in region b negatively affect potency, while region a interacts with a lipophilic pocket that can accommodate a variety of large quasi-planar substituents. Our study has identified a series of novel submicromolar NPBWR1 antagonists, including 7y (CYM50719), 9h (CYM50769) and 15e (CYM50775), all of which have higher potency than our previously reported lead compound 1. Among them, 9h was found to have high selectivity for a variety of pharmacologically significant non-targets after further analysis, and is therefore suitable for further development. We will publish the progress of medicinal chemistry research on this chemistry type in due course. [1]
|
| Molecular Formula |
C24H17CLN2O3
|
|---|---|
| Molecular Weight |
416.86
|
| Exact Mass |
416.093
|
| CAS # |
1421365-63-0
|
| PubChem CID |
50904505
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.315
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
693
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QHVSQUYCVUHYKT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H17ClN2O3/c1-29-15-10-12-16(13-11-15)30-23-21(25)14-26-27(24(23)28)22-19-8-4-2-6-17(19)18-7-3-5-9-20(18)22/h2-14,22H,1H3
|
| Chemical Name |
5-chloro-2-(9H-fluoren-9-yl)-4-(4-methoxyphenoxy)pyridazin-3-one
|
| Synonyms |
ML 250; ML250; ML-250; CYM 50769; 1421365-63-0; CYM 50769; CYM50769; 5-chloro-2-(9H-fluoren-9-yl)-4-(4-methoxyphenoxy)pyridazin-3-one; CHEMBL1972527; 5-chloro-2-(9H-fluoren-9-yl)-4-(4-methoxyphenoxy)pyridazin-3(2H)-one; ML250; MLS003675924; CYM-50769; CYM50769;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~239.89 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3989 mL | 11.9944 mL | 23.9889 mL | |
| 5 mM | 0.4798 mL | 2.3989 mL | 4.7978 mL | |
| 10 mM | 0.2399 mL | 1.1994 mL | 2.3989 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
